Phenylketonuria therapeutics market to reach a value of $272.70 million in 2019

The phenylketonuria therapeutics market in the US, the UK, Germany, Italy, France, Spain and Japan will collectively reach a value of $272.70 million in 2019.

New treatments within the phenylketonuria therapeutics market look set to revolutionise the lives of many patients. Restricted diets may soon be a thing of the past, as medication looks to conquer this rare enzyme mutation.

Phenylketonuria is a metabolic genetic disorder in which renders the enzyme phenylalanine hydroxylase (PAH) unable to metabolize the amino acid phenylalanine (Phe). Abnormally high levels of Phe accumulate in the blood and can affect brain development, leading to progressive mental retardation, brain damage and seizures.It affects around 700,000 people around the globe.

Phenylketonuria cannot be cured, but early diagnosis and strict treatment plans can sometimes offer patients an average life span and improve mental development.

Before 2007, a phenylalanine-restricted diet was the only available method of treatment, but the approval and subsequent launch of Kuvan (sapropterin dihydrochloride) in 2007 in the US has meant that medical advances now surpass dietary regimes.

The phenylketonuria therapeutics market currently remains largely untapped, and provides significant potential for companies who can develop new molecules with enhanced bioavailability, similar safety and efficacy profiles, and better responses from the wider patient pool.

For more information on the phenylketonuria therapeutics market, see the latest research: Phenylketonuria Therapeutics Market Report

Follow us on Twitter @CandMResearch